Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

Hepatitis C Virus Genotype 4 Infection Clinical Trial

— QUATTROTURBO  

Official title:

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02309450
• Other study ID #: ANRSHC33QUATTROTURBO
• Secondary ID: 2014-002724-27
• Status: Withdrawn
• Phase: Phase 2
• First received: October 31, 2014
• Last updated: February 1, 2016
• Start date: December 2014
• Est. completion date: August 2016

Study information

• Verified date: February 2016
• Source: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé)
• Study type: Interventional

Clinical Trial Summary

ANRS HC 33 is a pilot study to assess efficacy and safety of a DCV 3DAA therapy with Asunaprevir, Daclatasvir and BMS-791325 in HCV genotype 4-infected patients after failure of pegylated Interferon-Ribavirin regimen.

Proportion of patients with cirrhosis will be limited to 50% of all patients included, cirrhosis being defined as a METAVIR score of F4 on the liver biopsy or an hepatic impulse elastometry ≥ 14 kPa or a Fibrotest® result > 0,75.

Description:

The clinical trial is multi-centre, national, Phase 2, open-label, single-arm. The primary objective of this study is to assess, in HCV genotype 4-infected patients in failure to prior treatment with pegylated Interferon and Ribavirin bitherapy, the rate of sustained virological response (SVR) 12 weeks after 12 weeks of treatment with an all-oral combination of 3 DAAs in a Fixed-Dose-Combination (Asunaprevir 200 mg, Daclatasvir 30 mg and BMS - 791325 75 mg) twice a day.

Estimated enrollment is 60 patients during the enrolment period (9 months).

Schedule of assessments:

w4-w8 : screening D0 : Start of anti-HCV tritherapy (Asunaprevir + Daclatasvir + BMS-791325) w12: stop tritherapy w24: Sustained virological response SVR12 assessment (12 weeks post treatment) w36 : Sustained virological response SVR24 assessment (24 weeks post treatment)

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2016
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult =18 years

• Infection with HCV genotype 4, confirmed by detectable HCV RNA = 1000 IU/ml at pre-inclusion

• Failure to a prior treatment with pegylated Interferon and Ribavirin, with failure being defined as follows:

• Non-response: HCV viral load remaining detectable during and at the end of P/R treatment.

• Relapse: undetectable HCV viral load during P/R treatment and detectable after the end of the treatment.

• HCV breakthrough: undetectable HCV viral load during P/R treatment becoming detectable before the end of treatment.

• Anti-HCV treatment discontinued for at least the last 3 months

• Fibrosis at any stage, with documentation of the presence or absence of cirrhosis at the pre-inclusion visit:

• history of liver biopsy showing cirrhosis lesions (METAVIR F4), at any time in the patient's history, or

• good quality (length = 1 cm and = 5 portal spaces) liver biopsy dating from less than 18 months to establish the METAVIR, or

• hepatic impulse elastometry (Fibroscan®) dating from less than 6 months and of good quality (at least 10 measurements on an incidence with IQR of less than 30% of the median elastometry measured and a success rate of 60%) or

• interpretable Fibrotest® dating from less than 6 months The proportion of patients with cirrhosis will be limited to 50% of all patients included, cirrhosis being defined as a METAVIR score of F4 on the liver biopsy or an hepatic impulse elastometry = 14 kPa or a Fibrotest® result > 0,75.

• Men and women of a child-bearing age and their heterosexual partners must use adequate contraception during treatment and up to 8 weeks after the end of treatment for women, 12 weeks after the end of treatment for men.

• Written informed consent signed by the patient and the investigator (on the day of the pre-inclusion at the latest and before any examination required by the study) (article L1122-1-1 Public Health Code)

• Patients with Health insurance (Sécurité Sociale or Couverture Médicale Universelle)

Exclusion Criteria:

Medical history

• CHILD B or C cirrhosis

• Previous HCV therapy including HCV NS3 protease inhibitor, and/or HCV NS5A replication complex inhibitor and/or HCV NS5B polymerase inhibitor

Current condition

• Positive HBs Antigen

• Confirmed HIV-1 or HIV-2 infection

• Pregnant or breast-feeding women

• Transplant recipients

• Any evolutive ongoing malignant disease, including hepatocellular carcinoma, which will be specifically screened for before inclusion

• Consumption of alcohol which, in the investigator's opinion, will be an obstacle to the patient's participation and to his/her remaining in the study

• Drug addiction which, in the investigator's opinion, will be an obstacle to the patient's participation and to his/her remaining in the study. Patients included in a programme of substitution with methadone or buprenorphine could be included. The opinion of an addictology consultant is recommended for patients presenting with current drug use or drug use in the past year.

• Patients taking part in another clinical trial during the 30 days prior to inclusion

• Patient under guardianship, trusteeship or judicial protection

Biological criteria

• ALT = 5xULN

• Total bilirubin = 34 µmol/L, unless a documented history of Gilbert's disease

• Hb < 85 g/L

• Platelets < 50 000/mm3

• Kidney failure defined by creatinine clearance < 50mL/mn (MDRD formula)

• QTc > 440 msec for males or 460 msec for females

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatitis C
• Hepatitis C Virus Genotype 4 Infection

Intervention

Drug:
• .Asunaprevir, Daclatasvir and BMS - 791325
All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.

Locations

Country	Name	City	State
France	France	All the Regions of the Country

Sponsors (2)

Lead Sponsor	Collaborator
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)	Bristol-Myers Squibb

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HCV sustained virological response rate	The primary endpoint is the Sustained Virological Response Rate defined by an undetectable HCV RNA at W24, that is to say 12 weeks after the end of the DCV 3DAA therapy associating Asunaprevir, Daclatasvir and BMS - 791325 (SVR12). In case of premature total or partial interruption of HCV treatment, the primary endpoint will also be assessed at week 24.	week 24	No
Secondary	Number of patients with adverse events		up to week 36	Yes
Secondary	Treatment interruptions	Number of patients who totally or partially interrupt,treatment	from day 0 to week12	Yes
Secondary	Causes of treatment discontinuation	toxicity or side effects	form day 0 to week 12	Yes
Secondary	Self-reported symptoms	self-questionnaire (ANRS AC24 perceived symptoms scale)	Day 0, week 12, week 36	Yes
Secondary	Patients adherence rate	measured using the (ANRS) self -questionnaire	week 4, week 12	No
Secondary	HCV viral load		day 0, week 1, week 2, week 4, week 8, week 12, week 16, week 20, week 24, week 36.	No
Secondary	Evaluation of the relationship between HCV subtypic distribution at baseline (by sequencing of the HCV NS5B domain) and the virological kinetics and response		at screening	No
Secondary	Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir and/or BMS in case of virological failure		up to week 12	No
Secondary	Child-Pugh score (composite measure)	For cirrhotic patients; Encephalopathy None+1 Mild to moderate (grade 1 or 2)+2 Severe (grade 3 or 4)+3; Ascites None+1 Mild to moderate (diuretic responsive)+2 Severe (diuretic refractory)+3; Bilirubin (mg/dL) < 2+1 2-3+2 > 3+3; Albumin (g/dL) > 3.5+1 2.8-3.5+2 < 2.8+3; International normalized ratio < 1.7+1 1.7-2.3+2 > 2.3+3 Total score of 5-6 = Grade A (well compensated disease) Total score of 7-9 = Grade B (disease with significant functional compromise) Total score of 10-15 = Grade C (decompensated liver disease)	at screening	No
Secondary	Insulin resistance measured using the HOMA-IR score		Day 0, week 36	No
Secondary	Parameters that define metabolic syndrome		Day 0, week 36	No
Secondary	Evolution of liver fibrosis	Fibrotest® or imaging Fibroscan®. Fibrosis will be evaluated with the same method (Fibroscan® or Fibrotest®) at baseline and week 36.	Day 0, week 36	No
Secondary	MELD score (composite measure)	For cirrhotic patients; MELDScore = 10 * ((0.957 * ln(Creatinine)) + (0.378 * ln(Bilirubin)) + (1.12 * ln(INR))) + 6.43	at screening	No